8:00 am Coffee & Networking

Strategy – Selection – Characterization

8:20 am Chair’s Opening Remarks

  • Anderson Clark Director, Translational In Vivo Pharmacology, EMD Serono Research & Development Institute

8:30 am Preclinical Characterization of TSR-033, A Novel Therapeutic Antibody Targeting LAG-3

  • Geeta Sharma Scientific Fellow, Translational Research, Tesaro

Synopsis

  • Despite the clinical success of checkpoint therapies targeting the PD(L)-1 axis, a sizeable proportion of patients are non responsive. Alternative checkpoint receptors like LAG-3 are being investigated in order to benefit these non-responsive patients
  • TSR-033 is a humanized LAG-3 antibody that binds to and block the binding of LAG-3 to its ligand on T cells
  • This presentation covers the preclinical characterization of TSR-033 including various mouse tumor models which were used to evaluate efficacy and mechanism in combination with Anti-PD-1
  • TSR-033 is currently being evaluated in clinics

8:55 am Models to Understand the Mechanisms of Action of Cancer Biologic Therapies

  • Dan Powell Director, Clinical Tumor Tissue Facility & Associate Professor , University of Pennsylvania

9:20 am Immunoprofiling of Murine Tumor Models to Improve the Translational Prediction of Immune-Based Therapeutics

9:45 am Q&A Panel – Strategy – Selection – Characterization

  • Geeta Sharma Scientific Fellow, Translational Research, Tesaro
  • Dan Powell Director, Clinical Tumor Tissue Facility & Associate Professor , University of Pennsylvania

10:15 am Morning Refreshments

Precision Gene Editing for Disease Modeling and Target Validation (Purple Stream)

Chaired by: Esmaiel Jabbari Professor, University of South Carolina

 

11.05 Humanized Immune Checkpoints Preclinical Models for Assessing Anti-Tumor Response and MoA

Kader Thiam, Vice President of Transgenic Technologies, genOway


11.30 Transgenic Manipulation of Tumor Organoids for “Personalized” Modeling of Diverse Tumor Subtypes

Joshua Breunig, Assistant Professor, Cedars-Sinai Medical Center


11.55 Using 3D Tumor Models to Investigate the Role of Immune Cells on the CSC Niche

Esmaiel Jabbari, Professor, University of South Carolina


12.20 Q&A Panel - Precision Gene Editing For Disease Modelling & Target Validation

Kader Thiam, Vice President of Transgenic Technologies, genOway

Joshua Breunig, Assistant Professor, Cedars-Sinai Medical Center

Esmaiel Jabbari, Professor, University of South Carolina

Models and Strategies to Bridge the Combination Gap (Yellow Stream)

12:40 pm Lunch

1:40 pm Round Table Discussions

2:30 pm Moderator Feedback Panel

2:40 pm Afternoon Refreshments

Models Aiding Dose Translation and Understanding Drug Response

3:10 pm Challenges & Opportunities in Understanding Drug Exposure at The Site Of Action and The Potential Implications of Transporter Mediated Efflux

3:35 pm NCI’s Patient Derived Models Repository Quality Control and Preclinical Efforts

  • Yvonne Evrard Operations Manager , Frederick National Laboratory for Cancer Research

4:00 pm Q&A Panel – Models Aiding Dose Translation and Understanding Drug Response

  • Rhys Jones Senior Director DMPK , Pfizer
  • Yvonne Evrard Operations Manager , Frederick National Laboratory for Cancer Research

4:20 pm Close of Conference

  • Anderson Clark Director, Translational In Vivo Pharmacology, EMD Serono Research & Development Institute